WATERTOWN, Mass.--(BUSINESS WIRE)--Neumora Therapeutics, Inc. (Neumora), a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data ...
WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease ...
AbbVie's acquisition of Cerevel Therapeutics enhances its neuroscience pipeline with promising candidates Emraclidine and Tavapadon, expected to significantly boost revenues post-approval. Emraclidine ...
In the December 2 Nature Chemical Biology, researchers led by Jeffrey Conn at Vanderbilt University, Nashville, Tennessee, report that they have developed a small molecule that not only boosts the ...
Positive allosteric modulators (PAMs) of the muscarinic acetylcholine M4 receptor show potential against schizophrenia because they can enhance endogenous acetylcholine signaling, which in turn may ...
Researchers from Maplight Therapeutics Inc. presented preclinical data for the investigational muscarinic M1/M4 receptor agonist ML-007, being evaluated for the treatment of neuropsychiatric disorders ...
SAN DIEGO and TOKYO and CAMBRIDGE, England, Nov. 22, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Sosei Group Corporation ("Sosei Heptares"; TSE: 4565) announce the signing of ...
WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback